← FDA DRUG APPROVALS

FDA ANDA · ANDA201422

TOBRAMYCIN

Sponsor: HIKMA

APPLICATION
ANDA201422
TYPE
ANDA
ORIGINAL APPROVAL
2014-05-28
LATEST ACTION
2024-09-30
ROUTE
RESPIRATORY (INHALATION), INHALATION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

TOBRAMYCINPrescription
TOBRAMYCIN 300MG/5ML · SOLUTION · INHALATION

Approval history

2024-09-30Labeling · Supplement 9 · standardAP
2020-01-21Labeling · Supplement 4 · standardAP
2020-01-21Labeling · Supplement 3 · standardAP
2020-01-21Labeling · Supplement 1 · standardAP
2014-05-28Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →